$
1.145
-0.005(-0.435%)1D
  • Overview
  • Forecast
  • Valuation
  • Earnings
Line
Line
|
Candle
Candle
1D
5D
1M
3M
6M
YTD
1Y
5Y
High
1.160
Open
1.160
VWAP
--
Vol
4.54M
Mkt Cap
732.46M
Low
1.130
Amount
--
EV/EBITDA(TTM)
--
Total Shares
593.13M
EV
454.31M
EV/OCF(TTM)
--
P/S(TTM)
6.54
Geron Corporation is a commercial-stage biopharmaceutical company. The Company develops first-in-class telomerase inhibitor, RYTELO (imetelstat) for the treatment of adult patients with low- to intermediate-1 risk myelodysplastic syndromes (lower-risk MDS), with transfusion-dependent (TD) anemia requiring four or more red blood cell units over eight weeks who have not responded to or have lost response to or are ineligible for erythropoiesis-stimulating agents (ESAs). RYTELO is supported by the high unmet need in lower-risk MDS, including the observed benefit of RYTELO in difficult-to-treat subpopulations, such as patients with high transfusion burden and ring sideroblast negative (RS-) patients. It is also engaged in conducting a pivotal Phase III clinical trial of imetelstat in JAK-inhibitor relapsed/refractory myelofibrosis (R/R MF), as well as studies in other myeloid hematologic malignancies.
Show More

Market Estimates

Earnings Estimates
Revenue
YoY Chg
EPS
YoYChg
FY2025Q4
FY2025Q3
FY2025Q2
58.56M
+23.19%
--
--
52.66M
+86.28%
--
--
47.30M
+5263.2%
--
--
Estimates Revision
The market is revising Downward the revenue expectations for Geron Corporation (GERN) for FY2025, with the revenue forecasts being adjusted by -9.96% over the past three months. During the same period, the stock price has changed by -17.03%.
Revenue Estimates for FY2025
Revise Downward
down Image
-9.96%
In Past 3 Month
Stock Price
Go Down
down Image
-17.03%
In Past 3 Month
8 Analyst Rating
up Image
212.66% Upside
Wall Street analysts forecast GERN stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for GERN is 3.58 USD with a low forecast of 1.00 USD and a high forecast of 6.00  USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
5 Buy
2 Hold
1 Sell
Moderate Buy
up Image
212.66% Upside
Current: 1.145
sliders
Low
1.00
Averages
3.58
High
6.00
Goldman Sachs
initiated
$1
2025-07-10
Reason
Goldman Sachs resumed coverage of Geron with a Sell rating and $1 price target, which suggests 31% downside. The initial launch of the company's lead product and first commercial drug, Rytelo, has disappointed, and the near-term trajectory for the launch will be modest, the analyst tells investors in a research note.
Scotiabank
Greg Harrison
Outperform -> Sector Perform
downgrade
$1.50
2025-05-08
Reason
Scotiabank analyst Greg Harrison downgraded Geron to Sector Perform from Outperform with a $1.50 price target.
Scotiabank
Greg Harrison
Outperform -> Sector Perform
downgrade
$4
2025-05-08
Reason
Wedbush
Outperform -> NULL
downgrade
$7 -> $6
2025-05-08
Reason
Wedbush lowered the firm's price target on Geron to $6 from $7 and keeps an Outperform rating on the shares following quarterly results. Based on the firm's discussion with management, Wedbush believes both a lack of awareness of Rytelo overall, and an apparent wariness of cytopenias associated with Rytelo treatment are key issues for uptake - the firm sees these issues as fixable with recent HCP education efforts.
HC Wainwright & Co.
Emily Bodnar
Hold
Reiterates
n/a
2025-03-12
Reason
Needham
Gil Blum
Strong Buy
Reiterates
$5
2025-03-12
Reason

Valuation Metrics

The current forward P/E ratio for Geron Corp (GERN.O) is -9.66, compared to its 5-year average forward P/E of -8.57. For a more detailed relative valuation and DCF analysis to assess Geron Corp 's fair value, click here.

Forward PE

StronglyUndervaluedUndervaluedFairOvervaluedStronglyOvervalueddotted line Image
N/A
5Y Average PE
-8.57
Current PE
-9.66
Overvalued PE
-1.83
Undervalued PE
-15.31

Forward EV/EBITDA

StronglyUndervaluedUndervaluedFairOvervaluedStronglyOvervalueddotted line Image
N/A
5Y Average EV/EBITDA
-4.14
Current EV/EBITDA
0.00
Overvalued EV/EBITDA
17.45
Undervalued EV/EBITDA
-25.73

Forward PS

StronglyUndervaluedUndervaluedFairOvervaluedStronglyOvervalueddotted line Image
N/A
5Y Average PS
1467.09
Current PS
0.00
Overvalued PS
3099.50
Undervalued PS
-165.33

Financials

Annual
Quarterly
FY2025Q1
YoY :
+12927.30%
39.60M
Total Revenue
FY2025Q1
YoY :
-70.24%
-16.70M
Operating Profit
FY2025Q1
YoY :
-64.19%
-19.84M
Net Income after Tax
FY2025Q1
YoY :
-66.67%
-0.03
EPS - Diluted
FY2025Q1
YoY :
-100.00%
N/A
Free Cash Flow
FY2025Q1
YoY :
-3.05%
96.95
Gross Profit Margin - %
FY2025Q1
YoY :
-100.00%
N/A
FCF Margin - %
FY2025Q1
YoY :
-99.73%
-50.08
Net Margin - %

Trading Trends

Insider
Insiders are Neutral. There are no significant trading trends over the last month.
Sold
0-3
Months
0.0
USD
0
3-6
Months
0.0
USD
0
6-9
Months
0.0
USD
0
0-12
Months
0.0
USD
0
Bought
0-3
1
15.7K
USD
Months
3-6
0
0.0
USD
Months
6-9
3
206.2K
USD
Months
0-12
0
0.0
USD
Months
Hedge Fund
Hedge Funds areBuying! The buying amount has increased 226.92% over the last quarter.
Sold
0-3
Months
0.0
Volume
0
3-6
Months
0.0
Volume
0
6-9
Months
18.3M
Volume
3
0-12
Months
0.0
Volume
0
Bought
0-3
0
0.0
Volume
Months
3-6
5
81.6M
Volume
Months
6-9
4
25.0M
Volume
Months
0-12
0
0.0
Volume
Months
Congress Trading
Congress are Neutral. There are no significant trading trends over the last month.
Sold
0-3
Months
0.0
USD
0
3-6
Months
0.0
USD
0
6-9
Months
0.0
USD
0
0-12
Months
0.0
USD
0
Bought
0-3
0
0.0
USD
Months
3-6
0
0.0
USD
Months
6-9
0
0.0
USD
Months
0-12
0
0.0
USD
Months

GERN News & Events

Events Timeline

2025-05-07 (ET)
2025-05-07
07:17:44
Geron reports Q1 EPS (3c), consensus (4c)
select
2025-03-11 (ET)
2025-03-11
16:33:06
Geron announces EC approval of Rytelo
select
2025-03-11
16:04:00
Geron CEO Scarlett to leave company
select
Sign Up For More Events

News

7.0
07-18Globenewswire
Johnson Fistel, PLLP Investigates Claims on Behalf of Long-Term Shareholders of Geron Corporation, Viatris, Everus Construction, and SoundHound
6.0
07-10Benzinga
Goldman Sachs Initiates Coverage On Geron with Sell Rating, Announces Price Target of $1
5.0
06-18Newsfilter
Geron Corporation Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Sign Up For More News

FAQ

arrow icon

What is Geron Corp (GERN) stock price today?

The current price of GERN is 1.145 USD — it has decreased -0.43 % in the last trading day.

arrow icon

What is Geron Corp (GERN)'s business?

arrow icon

What is the price predicton of GERN Stock?

arrow icon

What is Geron Corp (GERN)'s revenue for the last quarter?

arrow icon

What is Geron Corp (GERN)'s earnings per share (EPS) for the last quarter?

arrow icon

What changes have occurred in the market's expectations for Geron Corp (GERN)'s fundamentals?

arrow icon

How many employees does Geron Corp (GERN). have?

arrow icon

What is Geron Corp (GERN) market cap?